Welcome to LookChem.com Sign In|Join Free

CAS

  • or
SUXIBUZONE IMPURITY C is an intermediate compound in the synthesis of Suxibuzone (S880000), which is a prodrug of the non-steroidal anti-inflammatory drug phenylbutazone. It plays a crucial role in the production of Suxibuzone, a medication used for alleviating joint and muscular pain.

23111-33-3

Post Buying Request

23111-33-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

23111-33-3 Usage

Uses

Used in Pharmaceutical Industry:
SUXIBUZONE IMPURITY C is used as an intermediate in the synthesis of Suxibuzone for the development of non-steroidal anti-inflammatory drugs (NSAIDs). It serves as a key component in the production process, enabling the creation of Suxibuzone, which is effective in treating joint and muscular pain.
Used in Pain Management:
SUXIBUZONE IMPURITY C contributes to the development of Suxibuzone, a prodrug that is transformed into phenylbutazone in the body. This transformation allows for the effective management of joint and muscular pain, providing relief to patients suffering from various conditions that cause discomfort in these areas.

Check Digit Verification of cas no

The CAS Registry Mumber 23111-33-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,1,1 and 1 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 23111-33:
(7*2)+(6*3)+(5*1)+(4*1)+(3*1)+(2*3)+(1*3)=53
53 % 10 = 3
So 23111-33-3 is a valid CAS Registry Number.
InChI:InChI=1/C20H22N2O3/c1-2-3-14-20(15-23)18(24)21(16-10-6-4-7-11-16)22(19(20)25)17-12-8-5-9-13-17/h4-13,23H,2-3,14-15H2,1H3

23111-33-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (S2400006)  Suxibuzone impurity C  European Pharmacopoeia (EP) Reference Standard

  • 23111-33-3

  • S2400006

  • 1,880.19CNY

  • Detail

23111-33-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-butyl-4-(hydroxymethyl)-1,2-diphenylpyrazolidine-3,5-dione

1.2 Other means of identification

Product number -
Other names 4-Hydroxymethylbutazolidine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:23111-33-3 SDS

23111-33-3Relevant articles and documents

A novel prodrug strategy for β-dicarbonyl carbon acids: Syntheses and evaluation of the physicochemical characteristics of C-phosphoryloxymethyl (POM) and phosphoryloxymethyloxymethyl (POMOM) prodrug derivatives

Dhareshwar, Sundeep S.,Stella, Valentino J.

experimental part, p. 2711 - 2723 (2011/04/15)

The C-phosphoryloxymethyl (POM) and phosphoryloxymethyloxymethyl (POMOM) prodrugs resulting from derivatization at the reactive α-carbon of β-dicarbonyl carbon acid drugs represent a unique approach for improving their chemical stability and aqueous solubility. This work evaluates the physicochemical and in vitro enzymatic bioconversion lability of selected prodrugs of phenylbutazone and phenindione. The POM and POMOM prodrug derivatives of phenylbutazone are highly water soluble (≥250 mg/mL), chemically stable with projected shelf-lives of 4.5 years (pH 3.5, 258C) and 1.1 years (pH 6.0, 25°C), respectively. Interestingly, both prodrug derivatives do not display a pH-dependency typical of many phosphate monoesters, although the similarities of their apparent thermodynamic activation parameters indicate a hydrolysis mechanism similar to other phosphates. These prodrugs undergo alkaline phosphatases catalyzed bioconversion to their respective carbon acids with an expected faster rate exhibited by the POMOM derivatives. Additionally, in marked contrast to the oxidative instability of phenindione, its POM prodrug is stable. The results from these studies reaffirm the rationale of transiently "masking" the reactive a-carbon/proton bond by covalently incorporating a POM or POMOM promoiety. This prodrug strategy presents a twofold advantage, enhancement of aqueous solubility and prevention of oxidative instability, two intrinsic formulation limitations found for β-dicarbonyl carbon acid drugs.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 23111-33-3